Scope of protection of claims and Markush formulae
Paul England explains the problems caused by the potentially very large number of compounds covered by a Markush formula.
More 
The role of experts in life sciences patent litigation
Paul England explores some of the challenges and paradoxes faced by parties instructing experts in patent litigation.
Largest damages award on cross-undertaking upheld on appeal
Paul England discusses the Court of Appeal decision in AstraZeneca v KRKA. More
Opening the door to open innovation
Amanda Rowell looks at the importance of the "open innovation" model in today's R&D world and analyses two successful instances of its implementation.
Strategic considerations - why opt-out or why not?
Anja Lunze analyses the strategic considerations relevant to a decision to opt-out of the UPC.
Scope of protection of claims and Markush formulae
Paul England explains the problems caused by the potentially very large number of compounds covered by a Markush formula when determining the scope of protection of claims.
More
The role of experts in life sciences patent litigation
Paul England explores some of the challenges and paradoxes faced by parties instructing experts in patent litigation.
Unitary patent fees proposals
Paul England discusses the considerations relevant to and proposals in respect of renewal fee levels under the new European unitary patent system.
Largest damages award on cross-undertaking upheld on appeal
Paul England discusses the Court of Appeal decision in AstraZeneca v KRKA upholding the largest award ever made by the Patents Court as a result of the discharge of a preliminary injunction. More
Opening the door to open innovation
Amanda Rowell looks at the importance of the "open innovation" model in today's R&D world.
Strategic considerations - why opt-out or why not?
Anja Lunze analyses the strategic considerations relevant to a decision to opt-out of the UPC.
Hearing, seeing, moving Part 2 - key issues in regulation and protection
Paul England explores the patent and complementary means of protecting neural prosthetic devices against the backdrop of regulation of medical devices. More
CTMs for "Chemicals for pharmaceutical use"
Chris Benson reports on the General Court's CTM decision.
Patentability of parthenogenic stem cells
Update on the patentability of parthenogenetically-activated ova and the most recent Advocate General's Opinion as to which cells should be considered "human embryos". More
Not all Bolar exemptions are the same
Christoph de Coster, Julia Bödeker and Paul England provide an important update explaining the varying scope of the Bolar exemptions.
Pharmaceutical trade mark confusion
Recent community trade mark case demonstrates the importance of assessing the likelihood of confusion between signs for life sciences products. More
Patentability of parthenogenic stem cells
Update on the patentability of parthenogenetically-activated ova and the most recent Advocate General's Opinion as to which cells should be considered "human embryos". More
Pharmaceutical trade mark confusion
Recent community trade mark case demonstrates the importance of assessing the likelihood of confusion between signs for life sciences products. More
Obtaining evidence of infringement: preservation and seizure
The second of two articles, we discuss the various methods of preservation and seizure of evidence. More
Who is entitled to a patent?
Members of our European team describe the key rules applying to patent entitlement in Austria, Germany and the UK.
What the new customs regulation means in practice
Roland Mallinson outlines the key points of the new customs legislation and their practical implications for rights holders. More
The importance of IP due diligence
When it is important to conduct it and why it is so important for a business that depends on IP assets.
Confidentiality and related protection
The subject of confidentiality protection arises in different forms and in a number of circumstances.
Supplementary protection certificates
This toolkit explains a number of key aspects of the SPC system and difficult issues that it has raised.
Protecting and enforcing intellectual property
Intellectual property is arguably the most important asset of any life sciences company, which means that ensuring its prompt and comprehensive protection is essential. This section explains these issues and provides guidance on how to enforce your IP in the case of a suspected infringement.